 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Lithostat |
| AHFS/Drugs.com | Consumer Drug Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.008.104 |
| Chemical and physical data | |
| Formula | C2H5NO2 |
| Molar mass | 75.067 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Acetohydroxamic acid (also known asAHA or by the trade nameLithostat) is adrug that is a potent and irreversibleenzyme inhibitor of theurease enzyme in variousbacteria andplants; it is usually used forurinary tract infections. The molecule is similar tourea but is nothydrolyzable by urease;[1] it thus disrupts the bacteria'smetabolism throughcompetitive inhibition.
In 1983 the USFood and Drug Administration approved acetohydroxamic acid (AHA) as anorphan drug for "prevention of so-calledstruvite stones" under the newly enactedOrphan Drug Act of 1983.[2] AHA cannot be patented because it is a standard chemical compound.[2]
